广发创新药ETF联接F(022104)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-58,140,264.38 |
93,184,903.44 |
103,040,927.26 |
-136,566,863.41 |
| 利息合计 |
116,348.40 |
218,782.45 |
89,770.64 |
160,275.61 |
| 其中:存款利息收入 |
116,348.40 |
218,782.45 |
89,770.64 |
160,275.61 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-8,950,802.41 |
-27,628,670.09 |
-33,465,908.77 |
-82,297,837.82 |
| 其中:股票投资收益 |
- |
740,209.06 |
-442,496.44 |
-6,748,053.44 |
| 基金投资收益 |
-9,200,906.52 |
-28,523,321.93 |
-33,130,163.62 |
-75,943,429.85 |
| 债券投资收益 |
250,104.11 |
35,709.57 |
- |
5,724.73 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
- |
118,733.21 |
106,751.29 |
387,920.74 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-50,261,529.13 |
119,141,136.04 |
136,147,646.88 |
-54,838,489.61 |
| 其他收入 |
955,718.76 |
1,453,655.04 |
269,418.51 |
409,188.41 |
| 费用 |
1,529,976.39 |
1,880,742.69 |
791,875.84 |
1,626,064.78 |
| 管理人报酬 |
199,047.80 |
285,485.16 |
131,345.78 |
325,165.22 |
| 基金托管费 |
39,809.56 |
57,096.99 |
26,269.12 |
65,033.09 |
| 销售服务费 |
1,146,015.97 |
1,353,381.00 |
544,272.67 |
1,057,682.33 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
54,296.68 |
7,383.58 |
- |
- |
| 其中:卖出回购金融资产支出 |
54,296.68 |
7,383.58 |
- |
- |
| 其他费用 |
90,380.96 |
177,395.96 |
89,988.27 |
178,184.14 |
| 利润总额 |
-59,670,240.77 |
91,304,160.75 |
102,249,051.42 |
-138,192,928.19 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年